N-nitroso-duloxetine

临床试验

计划入组 14 人 · 首次发布于 2023 年 4 月 4 日

已完成

NCT00494377

Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression

计划入组 940 人 · 首次发布于 2007 年 6 月 29 日

招募中

NCT05851976

Duloxetine for LBP

计划入组 120 人 · 首次发布于 2023 年 5 月 10 日

药物

查看全部 2189 →

Small Molecule

Approved

Duloxetine(Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly, Duloxetine Viatris (previously Duloxetine Mylan))

生产企业：Eli lilly and co

相关疾病：Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain，另有 6 项

C₁₈H₁₉NOS · Rx

gabapentin + duloxetine

N-0750

机构

查看全部 86 →

N&N Pharmaceuticals, Inc.

United States

n-Lorem Foundation

United States

Steve N Caritis Md

United States

资讯

查看全部 1833 →

3个月前

FDA Issues Class II Recall of Duloxetine Over Nitrosamine Impurity Risk

3个月前

Towa Pharmaceutical Recalls Duloxetine Over Nitrosamine Impurity; FDA Classifies as Class II Recall

去年

临床试验

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression

Duloxetine for LBP

药物

Duloxetine(Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly, Duloxetine Viatris (previously Duloxetine Mylan))

gabapentin + duloxetine

N-0750

机构

N&N Pharmaceuticals, Inc.

n-Lorem Foundation

Steve N Caritis Md

资讯

FDA Issues Class II Recall of Duloxetine Over Nitrosamine Impurity Risk

Towa Pharmaceutical Recalls Duloxetine Over Nitrosamine Impurity; FDA Classifies as Class II Recall

FDA Recalls 7,107 Bottles of Generic Duloxetine Over Carcinogenic Chemical Contamination